Pub Date : 2022-11-22DOI: 10.4274/mjima.galenos.2022.2022.39
A. Alici, Samet Cam
Introduction: Approximately 70-80% of diarrheal cases in children are caused by viral pathogens. Viral gastroenteritis agents include rotavirus and adenovirus 40 and 41, particularly in those under two years of age, while norovirus and sapovirus can cause epidemics in individuals of all ages. In this study, we investigated the effect of Coronavirus disease-2019 (COVID-19) pandemic measures on the incidences of rotavirus and enteric adenovirus, which are the main viral agents of acute gastroenteritis in the pediatric age group. Materials and Methods: Patients <18 years of age, who were admitted to Tatvan State Hospital with the suspicion of acute gastroenteritis and whose rotavirus and enteric adenovirus antigen stool tests were analyzed, were scanned retrospectively. One year of the pre-pandemic period (01.03.2019-29.02.2020) and 1 year of the pandemic period (01.03.2020-28.02.2021) were included in the study. The rotavirus and adenovirus monthly test numbers, positivity rates, age, and gender of the patients were evaluated. Results: A total of 1,438 pediatric patient samples were analyzed during the pre-pandemic period and 345 pediatric patient samples had a preliminary diagnosis of acute gastroenteritis during the pandemic period. The adenovirus positivity rate was 1.8% (n=26) and the rotavirus positivity rate was 12% (n=173) during pre-pandemic period. These rates were 0.8% (n=3) for adenovirus and 8.6% (n=30) for rotavirus during the pandemic period, (respectively p=0.215;p=0.080). A significant decrease in stool sample analyses was observed during the pandemic (p<0.001). Rotavirus positivity rates were significantly lower in October (p=0.001), November (p=0.04), and December (p=0.04) during the pandemic period compared to the same months during the pre-pandemic period. Conclusion: As a result, COVID-19 pandemic precautions, such as maintaining social distance, wearing a mask, and complying with hygiene rules may have decreased the incidence of acute gastroenteritis and consequently reduced the number of stool samples analyzed during the pandemic period. Precautions taken during the pandemic period helped to prevent intestinal viral infections in children.
{"title":"How Have the COVID-19 Pandemic Precautions Affected the Frequency of Rotavirus and Enteric Adenovirus in Pediatric Patients?","authors":"A. Alici, Samet Cam","doi":"10.4274/mjima.galenos.2022.2022.39","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2022.2022.39","url":null,"abstract":"Introduction: Approximately 70-80% of diarrheal cases in children are caused by viral pathogens. Viral gastroenteritis agents include rotavirus and adenovirus 40 and 41, particularly in those under two years of age, while norovirus and sapovirus can cause epidemics in individuals of all ages. In this study, we investigated the effect of Coronavirus disease-2019 (COVID-19) pandemic measures on the incidences of rotavirus and enteric adenovirus, which are the main viral agents of acute gastroenteritis in the pediatric age group. Materials and Methods: Patients <18 years of age, who were admitted to Tatvan State Hospital with the suspicion of acute gastroenteritis and whose rotavirus and enteric adenovirus antigen stool tests were analyzed, were scanned retrospectively. One year of the pre-pandemic period (01.03.2019-29.02.2020) and 1 year of the pandemic period (01.03.2020-28.02.2021) were included in the study. The rotavirus and adenovirus monthly test numbers, positivity rates, age, and gender of the patients were evaluated. Results: A total of 1,438 pediatric patient samples were analyzed during the pre-pandemic period and 345 pediatric patient samples had a preliminary diagnosis of acute gastroenteritis during the pandemic period. The adenovirus positivity rate was 1.8% (n=26) and the rotavirus positivity rate was 12% (n=173) during pre-pandemic period. These rates were 0.8% (n=3) for adenovirus and 8.6% (n=30) for rotavirus during the pandemic period, (respectively p=0.215;p=0.080). A significant decrease in stool sample analyses was observed during the pandemic (p<0.001). Rotavirus positivity rates were significantly lower in October (p=0.001), November (p=0.04), and December (p=0.04) during the pandemic period compared to the same months during the pre-pandemic period. Conclusion: As a result, COVID-19 pandemic precautions, such as maintaining social distance, wearing a mask, and complying with hygiene rules may have decreased the incidence of acute gastroenteritis and consequently reduced the number of stool samples analyzed during the pandemic period. Precautions taken during the pandemic period helped to prevent intestinal viral infections in children.","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"78 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80285203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-22DOI: 10.4274/mjima.galenos.2022.2022.38
Sinan Mermer, İ. Köksal
While the Coronavirus disease-2019 (COVID-19) pandemic has been going on for more than two years, the drug studies required for treatment still continue. As a result of these studies, molnupiravir, which has been approved for use in many countries in the treatment of COVID-19, has been put into use in our country with the guide published on February 12, 2022. One of the most important parameters required for a drug to be used at the appropriate dose and duration is its low side-effect profile. Molnupiravir is a generally well tolerated antiviral, and the most common side effects associated with its use are diarrhea, nausea, vomiting, headache, dizziness, and rash. In this report, it was aimed to present the details of the tremor symptom that developed during molnupiravir treatment in three patients we followed up.
{"title":"Can Tremor Be a Rare Side Effect Related to Molnupiravir?","authors":"Sinan Mermer, İ. Köksal","doi":"10.4274/mjima.galenos.2022.2022.38","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2022.2022.38","url":null,"abstract":"While the Coronavirus disease-2019 (COVID-19) pandemic has been going on for more than two years, the drug studies required for treatment still continue. As a result of these studies, molnupiravir, which has been approved for use in many countries in the treatment of COVID-19, has been put into use in our country with the guide published on February 12, 2022. One of the most important parameters required for a drug to be used at the appropriate dose and duration is its low side-effect profile. Molnupiravir is a generally well tolerated antiviral, and the most common side effects associated with its use are diarrhea, nausea, vomiting, headache, dizziness, and rash. In this report, it was aimed to present the details of the tremor symptom that developed during molnupiravir treatment in three patients we followed up.","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"20 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75035146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-16DOI: 10.4274/mjima.galenos.2022.2022.41
S. Izadi, M. Memarian, Zahra Shaabani Khatib, Samaneh Lavaf, Kamyar Mansori
{"title":"Comparison of the Effects of Continuous Renal Replacement Therapy and Hemodialysis on Complications, Vital Signs and Laboratory Parameters in patients with COVID-19","authors":"S. Izadi, M. Memarian, Zahra Shaabani Khatib, Samaneh Lavaf, Kamyar Mansori","doi":"10.4274/mjima.galenos.2022.2022.41","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2022.2022.41","url":null,"abstract":"","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"422 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84929811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-16DOI: 10.4274/mjima.galenos.2022.2022.40
Yakup Gezer, E. Tanrıverdi, B. Otlu, S. Yılmaz, Y. Bayindir
{"title":"Investigation of Fosfomycin Resistance Genes in Carbapenem-Resistant Enterobacterales Bloodstream Isolates of Liver Transplant Patients","authors":"Yakup Gezer, E. Tanrıverdi, B. Otlu, S. Yılmaz, Y. Bayindir","doi":"10.4274/mjima.galenos.2022.2022.40","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2022.2022.40","url":null,"abstract":"","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79811907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-18DOI: 10.4274/mjima.galenos.2022.2022.37
Y. Tanrıverdi Çaycı, O. S. Cirit, Ilknur Biyik, Canberk Çinar, Demet GÜR VURAL, K. Bilgin, A. Birinci
{"title":"Aminoglycoside-modifying Enzymes in Carbapenem-resistant Pseudomonas aeruginosa Clinical Isolates","authors":"Y. Tanrıverdi Çaycı, O. S. Cirit, Ilknur Biyik, Canberk Çinar, Demet GÜR VURAL, K. Bilgin, A. Birinci","doi":"10.4274/mjima.galenos.2022.2022.37","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2022.2022.37","url":null,"abstract":"","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"35 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87126702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-12DOI: 10.4274/mjima.galenos.2022.2022.36
Dilşah Başkol Elik, N. Oruç, Ezgi Güler, H. Erdem, Funda Karbek Akarca, O. Sipahi, A. Özütemiz, H. Pullukçu, M. Taşbakan, C. Çiçek, T. Yamazhan
Crimean-Congo hemorrhagic fever (CCHF) is an acute viral disease with fever and bleeding caused by a tick-borne virus belonging to the Bunyaviridae family. Coronavirus disease-2019 (COVID-19) is a novel disease caused by Severe Acute Respiratory Syndrome Coronavirus Type 2, which can lead to acute respiratory distress syndrome (ARDS). Here, we present a case with CCHF and COVID-19 co-infection to draw attention to the increased mortality in co-infection cases. A 77-year-old female patient with known hypertension was admitted to the emergency department with complaints of fever, nausea, vomiting, diarrhea, and myalgia for two days. There was no history of tick bite or contact with a patient with COVID-19. Current anamnesis and clinical and laboratory findings pre-diagnose the patient with CCHF, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura, leading to a ward admission. Crimean-Congo hemorrhagic fever was diagnosed after receiving a positive CCHF immunoglobulin M (indirect fluorescent antibody) result. A nasopharyngeal swab sample for COVID-19 real-time polymerase time reaction was sent due to a continuous fever and the development of shortness of breath on day three of hospitalization, which revealed positive results;thus, the patient was started on favipiravir treatment. The patient was transferred to the intensive care unit on day four due to increased oxygen demand and ARDS diagnosis. The patient died due to respiratory failure on the seventh day of hospitalization. COVID-19-related ARDS that overlapped on top of CCHF caused her to develop a cytokine storm and died despite her clinical parameter improvement due to CCHF. Crimean-Congo hemorrhagic fever and COVID-19 symptoms or findings can be confused because of their similarities, but the possibility of being seen together should not be overlooked. Concurrently, some similarities in the pathogenesis of these two diseases suggest that co-infection may worsen the clinical course;hence, new studies are needed on this subject.
{"title":"Increased Mortality with Co-existence of Crimean Congo Hemorrhagic Fever and COVID-19","authors":"Dilşah Başkol Elik, N. Oruç, Ezgi Güler, H. Erdem, Funda Karbek Akarca, O. Sipahi, A. Özütemiz, H. Pullukçu, M. Taşbakan, C. Çiçek, T. Yamazhan","doi":"10.4274/mjima.galenos.2022.2022.36","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2022.2022.36","url":null,"abstract":"Crimean-Congo hemorrhagic fever (CCHF) is an acute viral disease with fever and bleeding caused by a tick-borne virus belonging to the Bunyaviridae family. Coronavirus disease-2019 (COVID-19) is a novel disease caused by Severe Acute Respiratory Syndrome Coronavirus Type 2, which can lead to acute respiratory distress syndrome (ARDS). Here, we present a case with CCHF and COVID-19 co-infection to draw attention to the increased mortality in co-infection cases. A 77-year-old female patient with known hypertension was admitted to the emergency department with complaints of fever, nausea, vomiting, diarrhea, and myalgia for two days. There was no history of tick bite or contact with a patient with COVID-19. Current anamnesis and clinical and laboratory findings pre-diagnose the patient with CCHF, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura, leading to a ward admission. Crimean-Congo hemorrhagic fever was diagnosed after receiving a positive CCHF immunoglobulin M (indirect fluorescent antibody) result. A nasopharyngeal swab sample for COVID-19 real-time polymerase time reaction was sent due to a continuous fever and the development of shortness of breath on day three of hospitalization, which revealed positive results;thus, the patient was started on favipiravir treatment. The patient was transferred to the intensive care unit on day four due to increased oxygen demand and ARDS diagnosis. The patient died due to respiratory failure on the seventh day of hospitalization. COVID-19-related ARDS that overlapped on top of CCHF caused her to develop a cytokine storm and died despite her clinical parameter improvement due to CCHF. Crimean-Congo hemorrhagic fever and COVID-19 symptoms or findings can be confused because of their similarities, but the possibility of being seen together should not be overlooked. Concurrently, some similarities in the pathogenesis of these two diseases suggest that co-infection may worsen the clinical course;hence, new studies are needed on this subject.","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"13 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74917221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-08DOI: 10.4274/mjima.galenos.2022.2022.34
S. Ermin, G. Polat, C. Kıraklı
Introduction: The Coronavirus disease-2019 (COVID-19) has caused a serious pandemic. Thus, it is important to evaluate patients with data obtained at the first admission. Patients with severe disease should be recognized among patients admitted to the hospital symptomatically. This study aimed to examine the role of admission hemogram parameters in predicting prognosis in patients who were hospitalized for COVID-19. Materials and Methods: We enrolled all patients diagnosed with confirmed or probable COVID-19 retrospectively. Age, sex, smoking history, chronic disease, hemogram parameters [i.e., leukocytes, neutrophils, monocytes, lymphocytes, hemoglobin, hematocrit, platelets, neutrophillymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and lymphocyte-monocyte ratio (LMR)], D-dimer, ferritin, albumin, C-reactive protein, and lactate dehydrogenase were recorded. The relationship between hemogram parameters and poor prognosis was evaluated. The need for pulse-steroid therapy, transfer to the intensive care unit, and mortality indicated a poor prognosis. Results: The median age of the 156 patients enrolled in the study was 63 (24-94) years. Significant correlations were found in the univariate analysis between leukocytes, neutrophils, lymphocytes, monocytes, NLR, PLR, LMR, and poor prognosis (p=0.013, p=0.004, p=0.000, p=0.036, p=0.000, p=0.010, and p=0.025, respectively). In the multivariate analysis, significant correlations were found between leukocytes, NLR, and poor prognosis (p=0.04 and p=0.001, respectively). The cut-off value of the COVID-hemogram score was three points, with 87% sensitivity and 62% specificity. The scoring system determined the risk for a poor prognosis in patients. The median score was 7 (5-8) in those with a poor prognosis and 2 (0-6) in those who did not have a poor prognosis (p<0.001). Conclusion: Admission hemogram parameters can be used to predict a poor prognosis in patients hospitalized for COVID-19. The use of the COVIDhemogram score in the first admission will guide physicians in making treatment decisions.
{"title":"Can Hemogram Parameters Be Used to Predict the Prognosis in Hospitalized COVID-19 Patients?","authors":"S. Ermin, G. Polat, C. Kıraklı","doi":"10.4274/mjima.galenos.2022.2022.34","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2022.2022.34","url":null,"abstract":"Introduction: The Coronavirus disease-2019 (COVID-19) has caused a serious pandemic. Thus, it is important to evaluate patients with data obtained at the first admission. Patients with severe disease should be recognized among patients admitted to the hospital symptomatically. This study aimed to examine the role of admission hemogram parameters in predicting prognosis in patients who were hospitalized for COVID-19. Materials and Methods: We enrolled all patients diagnosed with confirmed or probable COVID-19 retrospectively. Age, sex, smoking history, chronic disease, hemogram parameters [i.e., leukocytes, neutrophils, monocytes, lymphocytes, hemoglobin, hematocrit, platelets, neutrophillymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and lymphocyte-monocyte ratio (LMR)], D-dimer, ferritin, albumin, C-reactive protein, and lactate dehydrogenase were recorded. The relationship between hemogram parameters and poor prognosis was evaluated. The need for pulse-steroid therapy, transfer to the intensive care unit, and mortality indicated a poor prognosis. Results: The median age of the 156 patients enrolled in the study was 63 (24-94) years. Significant correlations were found in the univariate analysis between leukocytes, neutrophils, lymphocytes, monocytes, NLR, PLR, LMR, and poor prognosis (p=0.013, p=0.004, p=0.000, p=0.036, p=0.000, p=0.010, and p=0.025, respectively). In the multivariate analysis, significant correlations were found between leukocytes, NLR, and poor prognosis (p=0.04 and p=0.001, respectively). The cut-off value of the COVID-hemogram score was three points, with 87% sensitivity and 62% specificity. The scoring system determined the risk for a poor prognosis in patients. The median score was 7 (5-8) in those with a poor prognosis and 2 (0-6) in those who did not have a poor prognosis (p<0.001). Conclusion: Admission hemogram parameters can be used to predict a poor prognosis in patients hospitalized for COVID-19. The use of the COVIDhemogram score in the first admission will guide physicians in making treatment decisions.","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"60 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77931028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-08DOI: 10.4274/mjima.galenos.2022.2022.35
Dilşah Başkol Elik, N. Oruç, Ezgi Güler, H. Erdem, Funda Karbek Akarca, O. Sipahi, A. Özütemiz, H. Pullukçu, M. Taşbakan, C. Çiçek, T. Yamazhan
Introduction: Data on the relationship between Coronavirus disease-2019 (COVID-19) and acute pancreatitis are limited. This study aimed to investigate the possible role of COVID-19 in the etiology of acute pancreatitis in a tertiary-care educational university hospital by retrospectively evaluating the incidence of acute pancreatitis in adult hospitalized patients with COVID-19. Materials and Methods: Severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) polymerase chain reaction (PCR)-positive adult inpatients from March 15, 2020, to February 1, 2021, constituted the study group in our hospital. This cohort was analyzed for acute pancreatitis criteria, including acute abdominal pain, increased amylase and/or lipase more than three times the normal value, and radiological finding supporting the disease. Patients who met at least two of the acute pancreatitis diagnostic criteria were determined, and those who met the criteria during or after SARS-CoV-2 PCR positivity detection were included in the study. These patients were further analyzed for COVID-19-related data and pancreatitis severity status. Results: Our hospital had 1227 inpatients with COVID-19 diagnosis in one year. A total of four cases met the inclusion criteria. Acute pancreatitis rates were detected at 0.3% and 1.07% for all cohorts (n=1227) and the pancreatic enzyme-tested group (n=372), respectively. Of these four patients, two (50%) were females (50%) and the mean age was 70.7 (range: 64-79) years. There was no correlation between COVID-19 pneumonia and pancreatitis severity scores, including Ranson, Acute Physiologic Assessment and Chronic Health Evaluation 2, and modified computed tomography severity scores. Conclusion: COVID-19 is a rare risk factor for acute pancreatitis and did not affect the pancreatitis severity or mortality in our cohort.
{"title":"Retrospective Evaluation of the Frequency of Acute Pancreatitis in Adult Hospitalized Patients with COVID-19 Infection","authors":"Dilşah Başkol Elik, N. Oruç, Ezgi Güler, H. Erdem, Funda Karbek Akarca, O. Sipahi, A. Özütemiz, H. Pullukçu, M. Taşbakan, C. Çiçek, T. Yamazhan","doi":"10.4274/mjima.galenos.2022.2022.35","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2022.2022.35","url":null,"abstract":"Introduction: Data on the relationship between Coronavirus disease-2019 (COVID-19) and acute pancreatitis are limited. This study aimed to investigate the possible role of COVID-19 in the etiology of acute pancreatitis in a tertiary-care educational university hospital by retrospectively evaluating the incidence of acute pancreatitis in adult hospitalized patients with COVID-19. Materials and Methods: Severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) polymerase chain reaction (PCR)-positive adult inpatients from March 15, 2020, to February 1, 2021, constituted the study group in our hospital. This cohort was analyzed for acute pancreatitis criteria, including acute abdominal pain, increased amylase and/or lipase more than three times the normal value, and radiological finding supporting the disease. Patients who met at least two of the acute pancreatitis diagnostic criteria were determined, and those who met the criteria during or after SARS-CoV-2 PCR positivity detection were included in the study. These patients were further analyzed for COVID-19-related data and pancreatitis severity status. Results: Our hospital had 1227 inpatients with COVID-19 diagnosis in one year. A total of four cases met the inclusion criteria. Acute pancreatitis rates were detected at 0.3% and 1.07% for all cohorts (n=1227) and the pancreatic enzyme-tested group (n=372), respectively. Of these four patients, two (50%) were females (50%) and the mean age was 70.7 (range: 64-79) years. There was no correlation between COVID-19 pneumonia and pancreatitis severity scores, including Ranson, Acute Physiologic Assessment and Chronic Health Evaluation 2, and modified computed tomography severity scores. Conclusion: COVID-19 is a rare risk factor for acute pancreatitis and did not affect the pancreatitis severity or mortality in our cohort.","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"45 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84821867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-28DOI: 10.4274/mjima.galenos.2022.2022.30
S. Tehrani, D. Yadegarinia, Afshin Bagherzade, L. Gachkar, Amirreza Keyvanfar
Introduction: Since the beginning of the Coronavirus disease-2019 (COVID-19) pandemic, scientists have studied many drugs to treat it, but none of them have been approved as a complete cure. Favipiravir is one of those drugs that effectively clears the body from the virus by interfering with the process of replication. This study aimed to determine the efficacy of favipiravir compared with supportive medication to treat moderate COVID-19 patients. Materials and Methods: In this randomized, open-label, controlled clinical trial, we examined the efficacy of favipiravir to treat moderate COVID-19 patients. The study was conducted in Labbafinejad Hospital (Tehran, Iran) from April to September 2021. A 1:1 ratio of eligible patients were assigned to the intervention and control groups. The control group received supportive medication. In addition to supportive medication, the intervention group received favipiravir. The primary endpoint was the hospitalization rate during the seven-day follow-up. And the secondary endpoints were symptoms, signs, and laboratory tests of the patients. Results: Out of 78 patients who were included in the study, 40 patients were assigned to the control group and 38 patients were assigned to the intervention group. At the beginning of treatment, the respiratory rate was higher in the intervention group (p=0.001), however, on the fifth (p=0.001) and seventh (p<0.001) days, it was significantly lower in the intervention group. In addition, oxygen saturation at the beginning of treatment was lower in the intervention group (p<0.001);however, on the fifth (p=0.016) and seventh (p<0.001) days, it was significantly higher in the intervention group. Furthermore, the consumption of favipiravir was not associated with the hospitalization rate (p=0.200). Conclusion: Favipiravir enhances respiratory manifestations in patients with moderate COVID-19 when compared to supportive medication alone.
{"title":"Efficacy of Favipiravir in the Treatment of Moderate COVID-19 Patients: A Randomized, Open-label, Controlled Clinical Trial","authors":"S. Tehrani, D. Yadegarinia, Afshin Bagherzade, L. Gachkar, Amirreza Keyvanfar","doi":"10.4274/mjima.galenos.2022.2022.30","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2022.2022.30","url":null,"abstract":"Introduction: Since the beginning of the Coronavirus disease-2019 (COVID-19) pandemic, scientists have studied many drugs to treat it, but none of them have been approved as a complete cure. Favipiravir is one of those drugs that effectively clears the body from the virus by interfering with the process of replication. This study aimed to determine the efficacy of favipiravir compared with supportive medication to treat moderate COVID-19 patients. Materials and Methods: In this randomized, open-label, controlled clinical trial, we examined the efficacy of favipiravir to treat moderate COVID-19 patients. The study was conducted in Labbafinejad Hospital (Tehran, Iran) from April to September 2021. A 1:1 ratio of eligible patients were assigned to the intervention and control groups. The control group received supportive medication. In addition to supportive medication, the intervention group received favipiravir. The primary endpoint was the hospitalization rate during the seven-day follow-up. And the secondary endpoints were symptoms, signs, and laboratory tests of the patients. Results: Out of 78 patients who were included in the study, 40 patients were assigned to the control group and 38 patients were assigned to the intervention group. At the beginning of treatment, the respiratory rate was higher in the intervention group (p=0.001), however, on the fifth (p=0.001) and seventh (p<0.001) days, it was significantly lower in the intervention group. In addition, oxygen saturation at the beginning of treatment was lower in the intervention group (p<0.001);however, on the fifth (p=0.016) and seventh (p<0.001) days, it was significantly higher in the intervention group. Furthermore, the consumption of favipiravir was not associated with the hospitalization rate (p=0.200). Conclusion: Favipiravir enhances respiratory manifestations in patients with moderate COVID-19 when compared to supportive medication alone.","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"204 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73938045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-28DOI: 10.4274/mjima.galenos.2022.2022.31
A. Baştuğ, M. Aksoy, F. Isli, O. Karabay
{"title":"Analysis of National Antifungal Consumption Data of Turkey Between 2013-2019","authors":"A. Baştuğ, M. Aksoy, F. Isli, O. Karabay","doi":"10.4274/mjima.galenos.2022.2022.31","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2022.2022.31","url":null,"abstract":"","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84556908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：